Azithromycin, furazolidone and omeprazol: A promising, low-dose, low-cost, short-term, anti-H. Pylori triple therapy

Coelho, L Gonzaga Vaz; Vieira, W. A.; Passos, Mcf; Chausson, Y.; Castro, FJ; Franco, Jmm; Moretzsohn, LD; Yazaki, FR; Costa, A. Queros da; Andrade, José Ivan de; Lp, Castro

doi:10.1016/s0016-5085(98)80379-x

Cited by 8 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2). [30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48] H2-receptor antagonist-based regimens achieved higher PER than PPI-based therapies which was marginally significant (P = 0.047). [49][50][51][52][53][54] Ranitidine bismuth citrate (RBC)-based triple therapy was just as effective as the PPI-based triple regimens (P = 0.06); however, there were only two studies including a small number of patients.…”

Section: Primary Treatment and Triple Therapiesmentioning

confidence: 99%

“…The role of M susceptibility was addressed in different ways. In papers directly comparing the efficiency of regimens containing F in M-susceptible strains, eradication rate was 83.0% (CI 75.5-91.3), while in patients harboring M-resistant strains, eradication was achieved in only 37% of the cases [31][32][33][34][35][36][37][38][39][40][41][42][43][44] (P = 0.001). 32,65,69 In direct comparative studies, regimens containing F achieved a figure of 81.3% (CI 73.0-88.3) versus schedules containing M at 67.3% (CI 58.8-76.4, P = 0.02).…”

Section: Factors Influencing the Rate Of Helicobacter Pylori Eradicationmentioning

confidence: 99%

See 1 more Smart Citation

Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection

Buzás¹,

Józan

2007

J of Gastro and Hepatol

View full text Add to dashboard Cite

Several aspects of Helicobacter pylori eradication have been meta-analyzed; however, nitrofuran-based therapies constitute an exception. The aim of this study was the systematic review and meta-analysis of the effect of furazolidone-and nitrofurantoin-based regimens in the eradication of infection. Studies evaluating the effects of nitrofurans on H. pylori were identified from Medline, EMBASE, the Cochrane Controlled Trials Register and congress abstracts. The studies were classified into groups based on first-, second-and third-line regimens. The pooled eradication rates and combined odd ratios of the individual studies were calculated and compared with the published meta-analysis. The factors influencing the efficiency of the regimens were also analyzed. Side-effects of nitrofuranbased regimens were also analyzed. The pooled eradication rate of primary proton pump inhibitor-based regimens containing furazolidone was 76.3% .2). The odds ratio for furazolidone-based regimens versus standard triple therapies was 2.34 (CI 0.76-3.92). Ranitidine bismuth citrate + furazolidone-based triple regimens were equally efficient (83.5%, CI 74.0-93.0, P = 0.06 versus triple therapies). Schedules including a H2 antagonist + furazolidone + one other antibiotic achieved pooled eradication rates of 79.9% (CI 67.8-89.9, P = 0.04). Bismuth-based triple therapies achieved 84.5% (CI 72.6-93.0, P = 0.002). Primary quadruple regimens containing furazolidone were superior to triple therapies (83.4%, CI 69.7-92.3, P = 0.01). Second-line schedules containing furazolidone obtained eradication rates of 76.1% (CI 66.4-85.0, P = 0.28 versus primary regimens). Third-line 'rescue' therapies were efficient in 65.5% of the cases (CI 56.3-75.5, P = 0.0001). Side-effects of the regimens containing furazolidone were more frequent than in standard therapies (P = 0.02). The combined odds ratio of side-effects for furazolidonebased versus standard therapies was 0.74 (CI 0.32-1.98). The duration of treatment, but not the furazolidone dose, influenced the treatment outcome. Primary triple regimens containing furazolidone are slightly less efficient than the standard primary combinations; primary quadruple regimens were more efficient than triple therapies. Furazolidone is also efficient as a component of second-line or rescue therapies.

show abstract

Section: Primary Treatment and Triple Therapiesmentioning

confidence: 99%

Section: Factors Influencing the Rate Of Helicobacter Pylori Eradicationmentioning

confidence: 99%

Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection

Buzás¹,

Józan

2007

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…However, clinical trials with azithromycin have displayed considerable variation with respect to the regimens used and the results obtained. Eradication rates varying between 93% and 22% have been reported (1,3,8,20,29,31) . In Brazil, few clinical trials have evaluated the role of azithromycin and furazolidone in the treatment of H. pylori infection and most of them have been performed in southeastern of the country (8,28) .…”

Section: Introductionmentioning

confidence: 99%

Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole based triple therapy: an open randomized clinical trial

Frota¹,

Cunha

Luz³

et al. 2005

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…The above mentioned characteristics make azithromycin an attractive choice to include in anti H. pylori regimens. So far multiple trials utilizing azithromycin based regimens with different methods, drug combinations, treatment durations, and with paradoxical results have been conducted (1,20,21,(30)(31)(32)(33)(34)(35)(36). Several studies obtained good efficacy in H. pylori eradication with short-term triple therapy using azithromycin, amoxicillin, and a proton pump inhibitor (33,37).…”

Section: Discussionmentioning

confidence: 99%

Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial

Sarkeshikian¹,

Iranikhah²,

Ghadir³

2009

Turk J Gastroenterol

View full text Add to dashboard Cite

clarithromycin, amoxicillin, and omeprazole and azithromycin, amoxicillin, and omeprazole, respectively, and completed the study course. Per protocol, eradication rate was 83% with clarithromycin, amoxicillin, and omeprazole and 75% with azithromycin, amoxicillin, and omeprazole (p =0.158). Eradication rate for a subgroup of patients with peptic ulcer disease in two groups were 83% and 74%, respectively (p=0.134

show abstract

Azithromycin, furazolidone and omeprazol: A promising, low-dose, low-cost, short-term, anti-H. Pylori triple therapy

Cited by 8 publications

References 0 publications

Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection

Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection

Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole based triple therapy: an open randomized clinical trial

Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial

Contact Info

Product

Resources

About